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Sarcopenia is characterized by a progressive skeletal muscle disorder that involves the loss of muscle mass and 
low muscle strength, which contributes to increased adverse outcomes. Few studies have investigated the 
association between chronic infection and sarcopenia. This study aimed to examine the association between 
human T-cell lymphotropic virus type-1 (HTLV-1) and sarcopenia. We conducted a cross-sectional study and 
enrolled 2,811 participants aged ≥ 40 years from a prospective cohort study in Japanese community dwellers 
during 2017–2019. Sarcopenia was defined as low appendicular skeletal muscle mass and low handgrip 
strength. The association between HTLV-1 seropositivity and sarcopenia was assessed using multivariable 
logistic regression. Odds ratio (OR) and 95% confidence interval (CI) of sarcopenia were analysed using HTLV-1 
seropositivity. We adjusted for age, sex, body mass index, physical activity, systolic blood pressure, glycated 
haemoglobin, low-density lipoprotein cholesterol, and smoking and drinking status. Of 2,811 participants, 484 
(17.2%) HTLV-1 infected participants were detected. HTLV-1 infection was significantly associated with 
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sarcopenia (adjusted OR 1.46, 95% CI 1.03–2.07, P = 0.034). HTLV-1 was associated with sarcopenia among 
community-dwelling adults. Active surveillance and early detection of asymptomatic HTLV-1 infection might be 
beneficial to reinforce countermeasures to inhibit the progress of HTLV infection-associated sarcopenia. 
INTRODUCTION 
 
Sarcopenia is characterized by a progressive and 
generalized skeletal muscle disorder that involves the 
accelerated loss of muscle mass and low muscle 
strength [1]. Sarcopenia, a major problem associated 
with aging, is listed in the International Classification 
of Diseases-10 code [2], and is associated with 
increased adverse outcomes including falls, disability, 
hospital admission, long term care placement, poor 
quality of life, and mortality [3–5]. Estimates of 
disease frequency have varied, but became more 
precise with the evolution of its definition. One of  
the lowest pooled prevalence estimates (12.9% [95% 
confidence interval; CI 9.9–15.5]) was calculated 
using a 2010 definition of the European Working 
Group on Sarcopenia in Older People [1, 6]. Sarcopenia 
has a medical and economic burden; the total estimated 
cost of hospitalizations of individuals with sarcopenia in 
the USA was USD $40.4 billion with a mean per person 
cost of USD $260 [7]. 
 
Factors that cause and worsen sarcopenia are 
categorised as primary and secondary. Known risk 
factors include changes in sex steroid hormones and 
cytokines associated with aging, genetic susceptibility 
(as primary sarcopenia), physical inactivity, smoking, 
low 1,25-OH vitamin D, low nutritional intake, low 
protein intake, and atherosclerosis (as secondary 
sarcopenia) [6, 8–17].  
 
A recent study reported that sarcopenia was more 
prevalent in a community cohort of human 
immunodeficiency virus (HIV) infection [18]. In the 
cross-sectional analysis of 315 HIV-infected cases and 
matched controls, sarcopenia was more prevalent in 
HIV-infected cases compared with matched controls 
[19]. Except for HIV infection, however, no study has 
investigated the association between chronic infection 
and sarcopenia. 
 
Human T-cell lymphotropic virus type-1 (HTLV-1) was 
the first retrovirus shown to cause diseases including 
adult T-cell leukaemia, HTLV-1 associated 
myelopathy/tropic spastic paraparesis, polymyositis and 
dermatomyositis [20–22]. HTLV-1-infected CD4+ T-
lymphocytes were found to infiltrate the muscle of 
patients with inflammatory myopathies, and cytotoxic 
T-lymphocyte immune reactions to the TAX gene 
induced tumour necrosis factor-alpha and cytotoxic 
effects on muscles [22]. However, little is known about 
the effect of HTLV-1 infection on muscles in 
asymptomatic carriers. 
 
We hypothesized that chronic inflammation caused by 
HTLV-1 infection has a negative impact on skeletal 
muscle and strength. However, the relationship between 
HTLV-1 infection and sarcopenia has not been 
investigated to date. The aim of this study was to 
investigate whether there is an association between 
HTLV-1 infection and sarcopenia and to examine whether 




General characteristics of the study population 
 
Among 2,811 participants with a mean age of 70 years 
(standard deviation [SD] ± 10.0), 502 (18%) HTLV-1-
infected participants were detected using a 
chemiluminescent enzyme immunoassay (CLEIA). 
Samples from 488 of these 502 participants were 
available for real-time PCR (RT-PCR) testing. Of these 
474 were positive for HTLV-1 and 14 were negative by 
RT-PCR. For the negative cases, western blotting 
showed that three cases were positive, one was 
negative, one was indeterminate, and Innogenetics line 
immunoassay showed that seven cases were positive, 
one was indeterminate, and one was negative. The 484 
(17%) participants who were positive for HTLV-1 by 
RT-PCR, western blotting or Innogenetics line 
immunoassay were included in the analysis. 
 
Table 1 shows the characteristics of participants with 
HTLV-1 infection. Compared with HTLV-1-uninfected 
participants, HTLV-1-infected participants included a 
lower proportion of men (29.1% vs 39.8%, P < 0.001), 
and those with older age (mean age 74.0 vs 69.4, P < 
0.001), lower weight (55.6 kg vs 57.8 kg, P < 0.001), 
lower handgrip strength (24.7 kg vs 28.4 kg, P < 0.001), 
lower appendicular skeletal muscle mass (ASM) (15.4 
kg vs 16.5 kg, P < 0.001), and higher proportion of 
antihypertensive drug use (50.6% vs 40.7%, P < 0.001). 
The body mass index (BMI), proportion of 
hypoglycaemic drug use, lipid-lowering drug use, 
physical activity, systolic blood pressure (SBP), 
glycated haemoglobin (HbA1c), high-density 
lipoprotein cholesterol (HDL), triglycerides (TG), high 
sensitive C-reactive protein (hs-CRP), and white blood 
cells (WBC) were not different between HTLV-1-
infected participants and HTLV-1-uninfected 
participants. 
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Table 1. Demographic and clinical characteristics of HTLV-1 infected and uninfected participants. 
 
HTLV-1 uninfected 
Mean ± SD or N (%) 
HTLV-1 infected 
Mean ± SD or N (%) 
P-value 
N 2327 (82.8)  484 (17.2)   
Age (year) 69.4 ± 10.1  74.0 ± 8.2  <0.001 c 
Sex (male) 925 (39.8)  141 (29.1)  <0.001 d 
Height (cm) 156.7 ± 8.8  153.3 ± 8.2  <0.001 c 
Weight (kg) 57.8 ± 10.4  55.6 ± 9.8  <0.001 c 
Body mass index 23.4 ± 3.1  23.6 ± 3.3 0.604 c 
Handgrip strength (kg) 28.4 ± 9.6  24.7 ± 8.8  <0.001 c 
Appendicular skeletal muscle mass (kg) 16.5 ± 4.1  15.4 ± 3.7  <0.001 c 
Sarcopenia 143 (6.2)  59 (12.2)  <0.001 d 
Smoking status   <0.001 d 
 Current 230 (9.9)  26 (5.4)   
 Past 568 (24.4)  92 (19.0)   
 Never 1529 (65.7)  366 (75.6)   
Drinking status   0.019 d 
 Current 850 (36.5)  145 (30.0)   
 Past 96 (4.1)  19 (3.9)   
 Never 1381 (59.4)  320 (66.1)   
Antihypertensive drug use 946 (40.7)  245 (50.6)  <0.001 d 
Hypoglycemic drug use 157 (6.8)  37 (7.6)  0.478 d 
Lipid-lowering drug use 483 (20.8)  108 (22.3) 0.444 d 
Physical activity 1.23 ± 0.76  1.23 ± 0.77 0.889 d 
Systolic blood pressure (mmHg) 134.8 ± 18.1  135.7 ± 18.1  0.214 c 
Diastolic blood pressure (mmHg) 75.7 ± 11.0  74.3 ± 10.5  0.018 c 
Glycated haemoglobin (%) 5.76 ± 0.55  5.77 ± 0.51  0.147 c 
Low-density lipoprotein cholesterol 
(mg/dl) 
122.2 ± 30.4  117.9 ± 29.9  0.014 c 
High-density lipoprotein cholesterol 
(mg/dl) 
61.8 ± 15.2  60.4 ± 15.0 0.055 c 
Triglycerides (mg/dl) 105.2 ± 60.8  106.5 ± 65.1  0.595 c 
High sensitive C-reactive protein (μg/dl) a (191, 389, 827) (190, 423, 923) 0.187 c 
White blood cells (/μl)b (4500, 5300, 6300) (4500, 5300, 6400) 0.503 c 
Data on high sensitive C-reactive protein and white blood cells were expressed as the median and interquartile range. 
a N=2712, b N=2804 
c P values from Wilcoxon rank sum test. 
d P values from McNemar chi-square test. 
 
Sarcopenia and HTLV-1 infection 
 
In univariable linear regression analysis, HTLV-1 
infection had a positive association with sarcopenia (ß = 
0.09, P < 0.001) (Table 2). The standardized ß 
coefficient was positively significant for age, 
antihypertensive agent use, hypoglycaemic agent use, 
SBP and WBC. This coefficient was inversely 
significant for male sex, height, weight, BMI, smoking 
and drinking status, diastolic blood pressure and HDL.  
 
In logistic regression analysis, HTLV-1 infection was 
significantly associated with low handgrip strength 
(odds ratio [OR] 2.06, 95% CI 1.62–2.62, P < 0.001). 
This association remained significant after further 
adjustment for age, sex, BMI, physical activity, SBP, 
HbA1c, low-density lipoprotein cholesterol (LDL), and 
smoking and drinking status (adjusted OR [aOR] 1.35, 
95% CI 1.04–1.76, P = 0.024) (Table 3). HTLV-1 
infection was associated with low skeletal muscle mass 
index  (SMI) (OR 1.24, CI 1.01–1.53, P = 0.040), but 
this association was not significant after further 
adjustment (aOR 1.11, 95% CI 0.87–1.40, P = 0.402). 
HTLV-1 infection was significantly associated with 
sarcopenia (OR 2.12, 95% CI 1.54–2.92, P < 0.001), 
and remained significant after further adjustment (aOR 
1.46, 95% CI 1.03–2.07, P = 0.034).  
 
We also tested the association between HTLV-1 
infection and sarcopenia among participants who were 
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Table 2. Univariable linear regression analysis for the effect of each exposure on handgrip strength, apendicular 






ß  P-value ß  P-value ß  P-value 
HTLV-1 infection -0.14  <0.001 -0.11  <0.001 0.09  <0.001 
Age (year) -0.38  <0.001 -0.24  <0.001 0.24  <0.001 
Sex (male) 0.71  <0.001 0.63  <0.001 -0.04  0.041  
Height (cm) 0.73  <0.001 0.74  <0.001 -0.22  <0.001 
Weight (kg) 0.57  <0.001 0.68  <0.001 -0.22  <0.001 
Body mass index 0.13  <0.001 0.27  <0.001 -0.14  <0.001 
Smoking status 0.51  <0.001 0.45  <0.001 -0.05  0.013 
Drinking status 0.42  <0.001 0.37  <0.001 -0.06  0.001 
Antihypertensive agent use -0.12  <0.001 -0.04  0.044 0.10  <0.001 
Hypoglycemic agent use -0.01  0.568 0.05  0.008 0.04  0.042 
Lipid-lowing drugs use -0.07  <0.001 -0.06  0.003 0.04  0.059 
Physical activity 0.03  0.166 0.01  0.673 -0.03  0.067 
Systolic blood pressure (mmHg) -0.08  <0.001 -0.08  <0.001 0.06  0.001 
Diastolic blood pressure (mmHg) 0.14  <0.001 0.09  <0.001 -0.04  0.045  
Glycated haemoglobin (%) -0.01  0.640  0.03  0.107 0.01  0.682 
Low-density lipoprotein cholesterol (mg/dl) -0.05  0.010  -0.07  <0.001 -0.03  0.102 
High-density lipoprotein cholesterol (mg/dl) -0.14  <0.001 -0.18  <0.001 -0.05  0.010  
Triglycerides (mg/dl) 0.08  <0.001 0.07  0.001 -0.02  0.348 
High sensitive C-reactive protein (μg/dl) a 0.00  0.935  0.04  0.019 0.03  0.172  
White blood cells (/μl) b 0.10  <0.001 0.07  <0.001 0.05  0.009 
a N=2712, b N=2804 
 
Table 3. Adjusted odds ratio and 95% confidence interval for HTLV-1 infection in relation to sarcopenia (N=2811). 
 
Low handgrip strength 
Low appendicular skeletal muscle 
mass index 
Sarcopenia 
 aOR 95% CI P-value aOR 95% CI P-value aOR 95% CI P-value 
Model 1 1.38  (1.06, 1.79) 0.016  1.09  (0.86, 1.37) 0.473  1.48  (1.05, 2.09) 0.027  
Model 2 1.35  (1.04, 1.76) 0.024  1.11  (0.87, 1.40) 0.402  1.46  (1.03, 2.07) 0.034  
Model 1. Adjusted for age, sex and body mass index. 
Model 2. Model 1 + physical activity, systolic blood pressure, glycated haemoglobin, low-density lipoprotein cholesterol, 
smoking and drinking status. 
aOR: adjusted odds ratio, CI: confidence interval. 
 
excluded as premenopausal women to avoid 
pre/postmenopausal changes to muscle mass and 
strength. The aOR did not differ after excluding 
premenopausal women (aOR 1.46, 95% CI 1.03–2.06, P 
= 0.035). 
 
Sarcopenia and inflammatory markers 
 
Logistic regression analysis was performed to examine 
the association between sarcopenia and inflammatory 
markers (logarithm of hs-CRP and WBC). Hs-CRP was 
significantly associated with low SMI after adjustment for 
age, sex, BMI, physical activity, SBP, HbA1c, LDL, and 
smoking and drinking status (aOR 1.19, 95% CI 1.10–
1.29, P < 0.001) (Table 4). WBC was significantly 
associated with low SMI and sarcopenia after adjustment 
(aOR 2.31, 95% CI 1.62–3.31, P < 0.001; aOR 3.26, 95% 




This community-based cross-sectional study 
demonstrated that asymptomatic HTLV-1 infection is a 
risk factor for sarcopenia. To the best of our knowledge, 
this is the first report to show chronic HTLV-1 infection 
is a risk factor for sarcopenia. In addition, inflammatory 
makers were identified as risk factors for low SMI and 
sarcopenia. 
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Table 4. Adjusted odds ratio and 95% confidence interval for sarcopenia in relation to inflammatory markers. 
Variable Model 
Low handgrip strength 
Low appendicular skeletal muscle 
mass index 
Sarcopenia 
aOR 95% CI P-value aOR 95% CI P-value aOR 95% CI P-value 
High sensitive CRP (logarithm)a        
 Model 1 1.04  (0.94, 1.15)  0.450  1.19  (1.10, 1.29) <0.001 1.12  (0.98, 1.27) 0.089  
 Model 2 1.04  (0.94, 1.14) 0.490  1.19  (1.10, 1.29) <0.001 1.10  (0.96, 1.25) 0.156  
White blood cells (logarithm)b         
 Model 1 1.44  (0.93, 2.23)  0.104  2.32  (1.64, 3.29) <0.001 3.37  (1.86, 6.11) <0.001 
 Model 2 1.46  (0.93, 2.29) 0.097  2.31  (1.62, 3.31) <0.001 3.26  (1.77, 5.99) <0.001 
Model 1. Adjusted for age, sex and body mass index. 
Model 2. Model 1 + physical activity, systolic blood pressure, glycated haemoglobin, low-density lipoprotein cholesterol, 
smoking and drinking status. 
a N=2712, b N=2804 
aOR: adjusted odds ratio, CI: confidence interval. 
 
Sarcopenia has recently been recognized as an emerging 
issue in HIV infection [18]. Multicenter AIDS cohort 
studies of over 7000 HIV patients’ in the USA reported 
that handgrip strength and walking speed declined more 
rapidly in HIV infected people compared with uninfected 
controls [23, 24]. In these studies, the authors suggested 
the possible mechanism of functional decline might have 
resulted from inflammation induced by co-infection with 
hepatitis C virus, diabetes mellitus, chronic kidney 
disease, or peripheral neuropathy. In a cross-sectional 
study in Malaysia, HIV-infected individuals had a higher 
proportion of sarcopenia defined by the Asian Working 
Group for Sarcopenia than HIV-uninfected individuals 
[17% (n = 8) vs 4% (n = 2), P = 0.049] [19]. In that 
study, the authors suggested that higher sarcopenia 
susceptibility in HIV-infected individuals was associated 
with chronic immune activation and inflammation. 
Contrary to symptomatic HIV infection under 
antiretroviral therapy, participants of our study were 
asymptomatic carriers of HTLV-1 infection and were not 
treated with any viral therapy. Therefore, there was no 
bias related to drug-induced modification of the 
association between HTLV-1 infection and sarcopenia in 
our study. Furthermore, our results suggested that HTLV-
1 infection might have a cumulative risk for sarcopenia, 
even in the asymptomatic phase.  
 
A putative mechanism of HTLV-1 associated 
sarcopenia is warranted. Potential explanations include 
anabolic resistance induced by inflammation and 
triggered catabolism. Because HTLV-1 promotes the 
production of cytokines such as interferon-gamma, 
tumour necrosis factor-alpha, and interleukin-6 [25], 
through the activation of nuclear factor-κB and  
cyclic AMP response element-binding protein [26], 
inflammatory factors might be induced even during 
asymptomatic infection. CRP and WBC are well-known 
surrogate markers of infection, and are activated by 
interleukin-6 or tumour necrosis factor-alpha produced 
by monocytes or macrophages. Inflammation 
contributes to the impaired mammalian/mechanistic 
target of rapamycin signalling (anabolic resistance), 
which leads to insufficient muscle protein synthesis 
[27]. Furthermore, inflammatory cytokines also promote 
protein catabolism [28]. 
 
Another putative pathway of HTLV-1 associated 
sarcopenia is an overabundance of reactive oxygen 
species (ROS). HTLV-1 encodes viral structural genes 
of the pX region encoding TAX, which increases the 
production of ROS [29, 30]. ROS, chemically unstable 
reactive free radicals that cause endothelial dysfunction, 
were reported as risk factors for sarcopenia [31]. ROS 
contribute to age-related deficits in muscle through 
increased oxidative damage to cell constituents and/or 
through the induction of defective redox signalling. 
ROS induced oxidative stress also damages other 
cellular components such as DNA, proteins, and lipids 
resulting in further damage to the cells and tissues. 
Consequently, the intra and intercellular membranes of 
the muscle fibres, in particular those of the sarcoplasmic 
reticulum, may be modified and the Ca2+ transport 
mechanism altered [32]. 
 
In a retrospective study, thirteen French HTLV-1 
infected-patients with polymyositis or dermatomyositis 
showed moderate muscle inflammation compared with 
HTLV-1 infected-controls without myopathy. However, 
the level of the proviral load did not differ between 
these groups [22]. Although a high proviral load is a 
major risk factor for adult T-cell leukaemia and HTLV-
1 associated myelopathy/tropic spastic paraparesis [33], 
level of proviral load was not a determinant of HTLV-1 
infection inducing muscle inflammation [22]. Therefore, 
even though HTLV-1 infected study participants  
were asymptomatic carriers, HTLV-1 infection may lead 
to subclinical muscle inflammatory reaction and 
sarcopenia. 
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The associations between HTLV-1 infection and low 
handgrip strength, and HTLV-1 infection and 
sarcopenia were significant, but not between HTLV-1 
infection and low SMI. These inconsistent results may 
be partially explained by the loss of muscle strength, 
which is typically clinically apparent before the loss of 
muscle mass. Data from a longitudinal study in 
Baltimore showed that a decline in muscle strength was 
much greater than that predicted by the decline in 
muscle mass [32]. 
 
Some limitations of the present study should be 
mentioned. First, as this was a cross-sectional study, we 
were not able to establish cause–effect relationships. 
Second, we had no data on the infectious period of each 
participant. Because effects of HTLV-1 infection on 
sarcopenia progression are thought to be cumulative, 
differences in the duration of infection may bias the 
results. Third, although the study participants were 
recruited from healthy community dwellers, we cannot 
deny the mixture of HTLV-1 infected-patients with 
polymyositis or dermatomyositis. However, although 
the association between HTLV-1 infection and 
sarcopenia was not significant, the same tendency was 
observed after excluding participants with joint pain  
(n = 639), which is a common symptom of 
inflammatory myopathy (aOR 1.47, 95% CI 0.98–2.21, 
P = 0.062) [34]. 
 
In conclusion, HTLV-1 was associated with sarcopenia 
in Japanese community dwellers. Similar to HIV 
infection, active surveillance and early detection of 
asymptomatic HTLV-1 infection might help reinforce 
countermeasures to prevent and inhibit the progress of 
HTLV-1 infection associated sarcopenia. 
 
MATERIALS AND METHODS 
 
Study settings and participants 
 
We conducted this cross-sectional study using data from 
the Nagasaki Islands Study, which was a prospective 
cohort study performed in Goto City in the western 
islands of Japan [35]. Details of the selection process 
and procedures of the examination in this study were 
published previously [35, 36]. 
 
The participants were recruited at medical check-ups, 
and members of the general population aged ≥ 40 years 
living in Goto City were targeted for enrolment. The 
Ethical Committee of Nagasaki University approved 
this study (project registration number: 14051404, 
20141002-5; Nagasaki, Japan), which was conducted 
according to the ethical standards defined in the 1964 
Declaration of Helsinki as well as its subsequent 
amendments. Written informed consent was obtained 
from all participants. Of 3,365 participants enrolled 
from 2017 to 2019, 2,811 participants were included 
after exclusion for the following: age <40 years (n = 
73), history of stroke (n = 155), BMI < 18.5 to avoid the 
effects of undernutrition on sarcopenia (n = 233), 
missing data for HTLV-1 serostatus (n = 14), handgrip 
strength (n = 7), ASM (n = 70), LDL (n = 1), and 
history of hypoglycaemic agent use (n = 1). Finally, 
2,811 participants (1,066 men and 1,745 women) with a 
mean age of 70.2 years (SD, 10.0 years; range, 40–97 
years) were evaluated.  
 
Data collection and laboratory measurements 
 
Body weight and height were measured with 
participants wearing light-weight clothes and without 
shoes, and the BMI was then calculated. Body 
composition was analysed by multi-frequency 
bioelectrical impedance analysis using InBody 430 
(InBody Japan, Tokyo, Japan). The muscle mass of the 
four limbs as ASM was summated. SMI (kg/m2) was 
calculated as the ASM (kg) divided by the square of the 
height (m) defined by Baumgartner’s formula [37]. 
Handgrip strength was recorded with the participant in a 
standing posture with his/her arm extended in a natural 
position. The handgrip dynamometer was adjusted for 
the participants so that their second proximal phalanxes 
were positioned around the handle. Handgrip strength 
was measured twice in both hands and the maximum 
scores of all recorded values for both sides were 
considered for analysis (Matsumiya Ika Seiki Seisakujo 
Smedley Dynamometer 0-1019-01). 
 
SBP and diastolic blood pressure (DBP) at rest were 
recorded with a blood pressure measuring device 
(HEM-907; Omron, Kyoto, Japan). The measurements 
were repeated when the SBP was ≥ 140 mmHg or DBP 
was ≥ 90 mmHg, and the mean values were used for 
analyses. We used a questionnaire to obtain information 
regarding each participant’s medical history of stroke, 
use of antihypertensive agents, hypoglycaemic agents, 
and lipid-lowering drugs. Smoking status and drinking 
status were categorized as “never”, “ex”, or “current”. 
Physical activity was evaluated using two questions: 
“Do you have a daily walking habit?” and “Do you 
regularly exercise more than 30 minutes in a day? (Yes, 
No)”. Physical activity was scored as the total sum of 
“Yes” answers to the two questions. 
 
Fasting blood samples were collected at the time of 
clinical examination. Blood samples were collected in 
an EDTA-2K tube, a siliconized tube, and a sodium 
fluoride tube. Samples from the EDTA-2K tube were 
used to measure the levels of WBC using an automated 
procedure at SRL, Inc. (Tokyo, Japan). Serum 
concentrations of LDL, HDL, TG, creatinine, HbA1c, 
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and hs-CRP were measured by standard laboratory 
procedures. 
 
Measurements of HTLV-1  
 
CLEIA kit (Fujirebio Inc., Tokyo, Japan) was used for 
HTLV-1 detection. As a confirmatory test, we used RT-
PCR using the Hydrolysis probe method with the 
LightCycler 480 (Roshe, Basel, Schweiz) as previously 
reported [38]. Sample DNA was purified from whole 
blood using GENE PREP STAR NA-480 (KURABO, 
Osaka, Japan). In addition, we used western blotting 
(Problot HTLV-1, Fujirebio Inc., Tokyo, Japan) or 
Innogenetics line immunoassay (INNO-LIA HTLV, 
Fujirebio Inc., Tokyo, Japan) for the RT-PCR-negative 
cases. 
 
Definition of sarcopenia 
 
Patients with a handgrip strength <26 kg for men and 
<18 kg for women, and SMI <7.0 kg/m2 for men and 
<5.7 kg/m2 for women were diagnosed as sarcopenia 
using Asian cutoff values [6, 39]. Low handgrip 
strength or low SMI were also defined using these 




Differences in mean values or proportions of variables 
by HTLV-1 positivity were analysed using the 
Wilcoxon rank sum test for continuous variables (age, 
height, weight, BMI, handgrip strength, ASM, physical 
activity, SBP, DBP, HbA1c, LDL, HDL, TG, hs-CRP 
and WBC), or the McNemar chi-square test for 
categorical variables (sex, sarcopenia, smoking status, 
drinking status, antihypertensive drug use, 
hypoglycemic drug use and lipid-lowering drug use). 
We performed simple linear regression analysis of 
handgrip strength and ASM as continuous variables. 
Then, we performed logistic regression analysis using 
clinical cutoff points of low handgrip strength, low SMI 
and sarcopenia. In the multivariable logistic regression 
analysis, adjustments were made a priori for age, BMI, 
SBP, HbA1c, LDL, physical activity (continuous 
variables), sex (dichotomous variable), and smoking 
and drinking status (categorical variable; never, ex, 
current: 1, 2, 3, respectively) [17, 35]. Age, sex, and 
BMI were included in adjustment Model 1. Age, sex, 
BMI, physical activity, SBP, HbA1c, LDL, and 
smoking and drinking status were included in Model 2. 
Because hs-CRP and WBC had a skewed distribution, 
they were expressed as the median and interquartile 
range, followed by logarithmic transformation.  
 
Because markers of chronic inflammation may play an 
important role in sarcopenia progression [14], we also 
evaluated the association between sarcopenia and 
inflammation markers (hs-CRP and WBC). For 
sensitivity analyses, we performed analysis among 
participants who were excluded as premenopausal 
women (n = 84) because menopause is associated with a 
decline in oestrogen that decreases muscle mass and 
strength [40]. All P values for statistical tests were two-
tailed and P < 0.05 was considered significant. All 
statistical analyses were performed using STATA v14 
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